Corbus Completes Enrollment For Dose Escalation Stage Of Phase 1 Trial For Nectin-4 Targeting ADC CRB-701; Initial Data Expected In Q1 2025
Portfolio Pulse from Benzinga Newsdesk
Corbus Pharmaceuticals has completed enrollment for the dose escalation stage of its Phase 1 trial for the Nectin-4 targeting ADC CRB-701. Initial data from this trial is expected in the first quarter of 2025.
October 16, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Corbus Pharmaceuticals has completed enrollment for the dose escalation stage of its Phase 1 trial for CRB-701, targeting Nectin-4. Initial data is anticipated in Q1 2025.
The completion of enrollment for the dose escalation stage of a Phase 1 trial is a significant milestone for Corbus Pharmaceuticals. It indicates progress in their drug development pipeline, which could positively impact investor sentiment and the stock price. The anticipation of initial data in Q1 2025 provides a timeline for potential future developments.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100